Experimental pancreatic cancer drug offers new hope in major trial

An experimental drug, daraxonrasib, for metastatic pancreatic cancer nearly doubled patient survival in a Phase 3 trial, significantly reducing death risk. The drug, targeting RAS proteins, has yet to gain FDA approval but has received expanded access permission, indicating regulatory progress.

This Wire brief sits within Fusion42's coverage of Biotech, and 48 sources have reported it between 26 Aug 2026 and 16 Oct 2026.